Combination of MRI prostate and 18F-DCFPyl PSMA PET/CT detects all clinically significant prostate cancers in treatment-naive patients: An international multicentre retrospective study.
Nishanthinie ParathithasanElisa PerryKim TaubmanJustin HegartyArpit TalwarLih-Ming WongThomas SutherlandPublished in: Journal of medical imaging and radiation oncology (2022)
Both mpMRI and 18F-DCFPyL-PSMA-PET/CT have high sensitivity for detecting csPCa with high agreement between modalities. There were no synchronous csPCa lesions detected on pathology that were not detected on imaging too.
Keyphrases
- pet ct
- prostate cancer
- end stage renal disease
- positron emission tomography
- ejection fraction
- newly diagnosed
- chronic kidney disease
- magnetic resonance imaging
- benign prostatic hyperplasia
- clinical trial
- high resolution
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- study protocol
- patient reported
- combination therapy
- fluorescence imaging